Solvay Healthcare’s Managing Director Dr John Peter explains how a focus on key research areas is delivering consistent growth in the competitive and at times contentious pharmaceuticals industry.
Written by James Hurley and produced by Paul Radbourne
Solvay Healthcare is the UK subsidiary of a major international pharmaceutical company and part of the multi-national Solvay Group, a successful chemicals, plastics and pharmaceuticals organization with a turnover of €9.4 billion.
Based in Southampton, Solvay Healthcare is developing on ongoing strategy that focuses on treatments for cardiovascular disease and research into neuroscience. The company employs over 160 people and has a turnover of approximately £50 million.
The corporation’s main areas of focus - neurology and cardiovascular – are complimented by some significant work in gastroenterology. “The World Health Organisation publishes the top eight research areas where work is needed each year, and we’re working in five of those eight,” says Dr John Peter, Managing Director of Solvay Healthcare in the UK. “We feel we’re quite well focused in terms of society’s needs.”
Dr Peter is something of a renaissance man – at least within the broad confines of the medical and pharmaceutical industries. Beginning his career as a dentist, he then decided that he wanted to work as a facial surgeon, so he became a doctor.
“My next move was into the pharmaceutical industry, working in research with a company called Duphar in the Netherlands,” he explains. When Duphar was bought by Solvay, Dr Peter moved over to the marketing side of the business in Germany. From there, he migrated to the company’s new business operations in Holland before coming back to the UK in 1992 as head of the UK & Ireland Pharmaceuticals operation.
An industry challenge
The pharmaceutical industry is finding…
To read the full article, click here
Bookmark with:
- Digg
- Reddit
- Del.icio.us
- Facebook
- Newsvine
Sign Up to Exec UK now for FREE!